SAGE SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Core Viewpoint - A class action lawsuit has been filed against Sage Therapeutics, Inc. for alleged violations of federal securities laws, claiming that the company made materially false and misleading statements regarding its drug efficacy and regulatory prospects [1][2][3]. Class Definition - The lawsuit seeks to recover damages for all individuals and entities that purchased or acquired Sage securities between April 12, 2021, and July 23, 2024, inclusive [2]. Case Details - The Complaint alleges that throughout the Class Period, the defendants made false statements regarding: - The effectiveness of zuranolone in treating Major Depressive Disorder (MDD), suggesting it was less effective than claimed [3] - The likelihood of FDA approval for the Zuranolone New Drug Application (NDA) for MDD, which was deemed unlikely in its current form [3] - The effectiveness of SAGE-718 in treating Mild Cognitive Impairment (MCI) due to Parkinson's Disease (PD), which was overstated [3] - The effectiveness of SAGE-324 in treating Essential Tremor (ET), which was also overstated [3] - As a result, the company's public statements were materially false and misleading at all relevant times [3]. Next Steps - A class action lawsuit has been filed, and investors who suffered losses in Sage have until October 28, 2024, to request to be appointed as lead plaintiff [4]. Cost Structure - The law firm represents investors on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorneys' fees if successful [5]. Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that has recovered hundreds of millions of dollars for investors in securities fraud class actions [6].